Protein tyrosine kinases and nitric oxide (NO) play important roles in several cardiovascular diseases. In this study, we examined the actions of two compounds, each has structure of genistein (a tyrosine kinase inhibitor) and an NO donor, on endotheliumindependent relaxation responses in the isolated rat aorta. By rational drug design, genistein was modified to acquire an NO donor, and we synthesized two such compounds (G-II, G-VI). These compounds and genistein induced dose-dependent relaxation responses in endothelium-denuded aortic strips, the rank order of potencies being G-VI > G-II > genistein. Incubation of endothelium-denuded strips with 1H-[1,2,4] oxadiazolo[4,3-a]-quinoxalin-1-one (ODQ, 10 µM), a guanylyl cyclase inhibitor, inhibited both the G-IIand G-VI-induced relaxations, but not the genistein-induced relaxation. The residual relaxations induced by these two compounds were similar to the genistein-induced relaxation. Incubation of endothelium-denuded strips with lysophosphatidylcholine (LPC, 20 µM)-which is a major atherogenic lysophospholipid component of oxidized lowdensity lipoprotein and is known to activate tyrosine kinase-caused a significant rightward shift in the dose-response curve for genistein. LPC also shifted the G-II-and G-VI-induced relaxation curves to the right; however, these relaxations in the presence of LPC were greater than that induced by genistein. The sodium nitroprusside-induced relaxation in endothelium-denuded strips was similar between in the absence and presence of LPC. These results suggest that each of our newly developed G-II and G-VI compounds has a dual action, as an NO donor and a tyrosine kinase inhibitor. These compounds may be useful against certain cardiovascular diseases.
Introduction
Nitric oxide (NO), a soluble gas continuously synthesized by the endothelium, has a wide range of biological activities, by which it helps to maintain vascular homeostasis by, for example, Correspondence to: Prof. Katsuo Kamata, Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Ebara 2-4-41, Shinagawa-ku, Tokyo 142-8501, Japan Phone: +81-3-5498-5856 Fax: +81-3-5498-5856 e-mail: kamata@hoshi.ac.jp modulating vascular tone and regulating local cell growth (Cannon, 1998; Matsumoto et al., 2004a; Triggle et al., 2004) . Further, numerous studies have demonstrated that NO has a variety of antiatherogenic actions on the vascular system, such as inhibitory effects on the (a) growth of vascular smooth muscle cells, (b) platelet aggregation, and (c) leukocyte adhesion to the endothelium. It is likely that decreased NO bioactivity leads to significant changes in vascular homeostasis and to the promotion of atherogenesis (Lloyd-Jones and Bloch, 1996; Busse and Fleming, 1996) .
A growing body of evidence suggests that lysophosphatidylcholine (LPC)-a principal component of oxidatively (ox) modified forms of low-density lipoproteins (LDL)-can modulate vascular cell-activation processes, culminating in the gene expression of various cytokines, growth factors, and other proteins associated with vascular diseases (Kume et al., 1992; GouniBerthold and Sachinidis, 2004) . It is well documented that LPC inhibits the endotheliumdependent relaxations mediated by both endothelium-derived relaxing factor (EDRF) and endothelium-derived hyperpolarizing factor (EDHF), and it is likely that LPC causes vascular spasm (Kugiyama et al., 1990; Fukao et al., 1995; Kamata and Nakajima, 1998) . It has also been reported that LPC has a mitogenic effect on vascular smooth muscle cells (Chen et al., 1995) and that activation of membrane or cytoplasmic tyrosine kinases may play a key role in LPC-induced mitogenic signaling responses (Bassa et al., 1999) . Moreover, Ozaki et al. (1999) showed that in bovine aortic endothelial cells, LPC activates the mitogen-activated protein kinase (MAP) cascade involving extracellular signal-regulated protein kinase (ERK) and c-jun N-terminal kinase (JNK) by a tyrosine kinase-dependent pathway. In our previous studies on the endothelium-denuded rat aorta, we observed that while LPC did not itself produce contraction, it did enhance the vascular contractile responses induced by high-K + , UK14,304 (5-bromo-6-[2-imidazolin-2-yl-amino]-quinoxaline) (a selective α2-adrenoceptor agonist), and phorbol ester (Suenaga and Kamata, 1998; Suenaga and Kamata, 1999) . Moreover, we recently reported that the potentiating effect of LPC on contractions of the rat aorta is accompanied by an increase in the tyrosine-phosphorylation of proteins, and that both genistein and tyrphostin B42 attenuate the potentiating effect of LPC on high-K + -induced contractions (Suenaga and Kamata, 2002) .
The tyrosine kinase pathway is known to be associated with cell growth, differentiation, and proliferation (Ullrich and Schlessinger, 1990) . However, an accumulating body of evidence suggests that these kinases also contribute to the signaling processes that lead to contraction in vascular smooth muscle (Hollenberg, 1994; Berk and Corson, 1997) . For example, growth factors such as epidermal growth factor and platelet-derived growth factor have been found to produce vascular contractions (Berk and Alexander, 1989) . Moreover, the contractile responses induced by some G-protein-coupled agonists [such as angiotensin-II, noradrenaline (NA), and 5-hydroxytryptamine (5-HT)] are attenuated by tyrosine kinase inhibitors in several arteries (Jinsi et al., 1996; Watts et al., 1996; Tasaki et al., 2003) .
Thus, it is conceivable that a concomitant blockade of tyrosine kinase activity and NOdonating activity might have beneficial effects in several vascular diseases. For that reason, we synthesized two different compounds which have chemical structures of genistein and an NO donor. Then, to investigate whether either of these compounds has a dual action as a tyrosine kinase inhibitor and NO donor, we performed experiments to examine their effects on vascular relaxation responses in the endothelium-denuded rat aorta.
Methods

General
This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals adopted by the Committee on the Care and Use of Laboratory Animals of Hoshi University (which is accredited by the Ministry of Education, Culture, Sports, Science and Technology, Japan). 
Preparation of aortic strips
Male Wistar rats, 18-20 weeks old, were anesthetized with diethyl ether and euthanized by decapitation. The thoracic aorta strip was prepared by the method described previously by us (Kobayashi et al., 2000; Kanie et al., 2003; Kobayashi et al., 2004; Matsumoto et al., 2004b) .
Briefly, a section of the aorta from between the aortic arch and the diaphragm was then removed and placed in oxygenated, modified Krebs-Henseleit solution (KHS). This solution consisted of (in mM) 118.0 NaCl, 4.7 KCl, 25.0 NaHCO3, 1.8 CaCl2, 1.2 NaH2PO4, 1.2 MgSO4, and 11.0 dextrose. The aorta was cleaned of loosely adhering fat and connective tissue, then cut into helical strips 3 mm in width and 20 mm in length. Each tissue was placed in a well-oxygenated (95% O2, 5% CO2) bath of 10 ml KHS at 37°C, with one end connected to a tissue holder and the other to a force-displacement transducer (Nihon Kohden, TB-611T). The tissue was equilibrated for 60 min under a resting tension of 1.0 g, which was found to be optimal for inducing maximal contractions in preliminary experiments. The endothelium was removed by rubbing the intimal surface with a cotton swab, successful removal being functionally confirmed by the absence of a relaxation to 10 µM ACh. For the relaxation studies, the aortic strips, which were weighed at the end of each experiment, were precontracted with an equieffective concentration of NA (1 × 10 -8 -7 × 10 -8 M) [i.e., so that the tension developed in response to NA was similar among groups pretreated with vehicle (1058.9 ± 35.0 mg, n=40), ODQ (1038.1 ± 33.3 mg, n=23), and LPC (1125.8 ± 51.1 mg, n=27)]. When the NA-induced contraction had reached a plateau level, genistein (10 -9 -10 -5 M), G-II (10 -9 -10 -5 M), G-VI (10 -9 -10 -5 M), or SNP (10 -10 -10 -7 M) was added in a cumulative manner. After the addition of sufficient aliquots of one of the above agents to produce the chosen concentration, a plateau response was allowed to develop before the addition of the next dose of the same agent. To investigate the effects of 10 -5 M ODQ and 2 × 10 -5 M LPC on the relaxation responses, the strip was incubated for 30 min in the appropriate medium before the cumulative addition of the drug.
Statistical analysis
Data are expressed as the mean ± S.E.M. When appropriate, statistical differences were assessed by means of Dunnett's test for multiple comparisons after a one-way analysis of variance, a probability level of P<0.05 being regarded as significant. Statistical comparisons between concentration-response curves were made by means of a two-way ANOVA, with Bonferroni's correction for multiple comparisons being performed post hoc (P<0.05 again being considered significant). Values for 50% effective concentration (EC50) were obtained by linear regression analysis. 
Results
Relaxation responses to genistein, G-II, and G-VI in endothelium-denuded aortic strips
When the contraction induced by NA (1 × 10 -8 -7 × 10 -8 M) in endothelium-denuded aortic strips had reached a plateau, genistein (10 -9 -10 -5 M), G-II (10 -9 -10 -5 M), or G-VI (10 -9 -10 -5 M) was added cumulatively. The results are summarized in Fig. 2 and Table 1 . Each of the drugs (10 -9 -10 -5 M) caused a concentration-dependent relaxation, with the maximum response at 10 -5 M. The maximum responses and EC50 values are shown in Table 1 . From these data, the rank order of potencies for relaxation was G-VI > G-II > genistein. 
Effects of a guanylyl cyclase inhibitor on genistein-, G-II-, and G-VI-induced relaxations
To determine whether our synthesized compounds really were NO-donors, we performed a series of experiments in which either G-II (10 -9 -10 -5 M) or G-VI (10 -9 -10 -5 M) was added cumulatively to endothelium-denuded strips precontracted by NA (1 × 10 -8 -7 × 10 -8 M) in the presence of 10 µM ODQ, a guanylyl cyclase inhibitor. Both the G-II-and G-VI-induced relaxations were significantly inhibited in the presence of ODQ (Fig. 3, Table 1 ). On the other hand, the genistein (10 -9 -10 -5 M)-induced relaxation was not altered by ODQ treatment (Fig. 3 , Table 1 ).
Effects of LPC on genistein-, G-II-, and G-VI-induced relaxations
As reported previously (Suenaga and Kamata, 2002) , LPC acts as a modulator of vascular tone via tyrosine kinase activation. To determine whether our synthesized compounds might modulate this LPC-induced effect, we examined their relaxing effects, and that of genistein, in the presence of LPC. In endothelium-denuded aortic strips, incubation with LPC (2 × 10 -5 M)
significantly decreased the maximal relaxation and sensitivity to each of the three drugs (Fig. 4 , Table 1 ). However, when the entire dose-response curve for each drug was analyzed, only the genistein-induced relaxation showed a significant rightward shift (Fig. 4) .
Relaxation responses induced by SNP
When the contraction induced by NA (1 × 10 -8 -7 × 10 -8 M) had reached a plateau, SNP (10 -10 -10 -7 M) was added cumulatively (Fig. 5) , the relaxation induced by SNP was not significantly different between the vehicle-and LPC (2 × 10 -5 M)-treated groups. However, the SNP-induced relaxation was completely blocked in the presence of ODQ (10 -5 M). 
Discussion
We found in the present study that each of our synthesized genistein/NO-donor compounds (G-II, G-VI) functioned as a dual-action tyrosine kinase inhibitor and NO donor in the rat aorta.
The mechanism underlying NO-induced relaxation has been intensively investigated (Gewaltig and Kojda, 2002; Ignarro, 2002) . After activation of soluble guanylyl cyclase by NO, cGMP is formed, and this in turn stimulates cGMP-dependent protein kinases. Subsequently, concentration (Gewaltig and Kojda, 2002) . Regarding tyrosine kinase inhibitors (such as genistein), it has been shown that (a) antagonize the vascular contractions a wide range of contractile agents, and (b) reduce resistance in a number of arteries in vitro, such as the rat mesenteric artery (Toma et al., 1995) , aorta (Duarte et al., 1997) , and renal artery (Gimenez et al., 1998) in vitro. The underlying mechanisms include a reversible inhibition of the increase in intracellular [Ca 2+ ] within vascular smooth muscle cells (Di Salvo et al., 1997) , and a regulation of the effect of Ca 2+ on the contractile apparatus within such cells (Toma et al., 1995) . When the relaxation responses induced by our two new compounds were compared with that of genistein in the endothelium-denuded rat aorta, the rank order of potencies for relaxation was G-VI > G-II > genistein (Fig. 2) . Moreover, the G-VI-and G-II-induced relaxations remaining in the presence of ODQ were similar to the genistein-induced relaxation (Fig. 3) . These results suggest that in the present preparation, NO and tyrosine kinase inhibition act synergistically to induce vascular smooth muscle relaxation, and that our G-VI and G-II compounds do indeed act as NO-donating agents. LPC, a well-characterized atherogenic component of ox-LDL, is generated during the oxidation of LDL and accumulates in atheroma. LPC causes an endothelial dysfunction that is characterized by an impairment of NO release, an expression of adhesion molecules, and an expression of growth factors (Kugiyama et al., 1990; Kume et al., 1992) . LPC also acts on the vascular smooth muscle cell (VSMC), and it induces both proliferation/release of fibroblast growth factor-2 and a Ca 2+ influx in cultured VSMC (Stoll and Spector, 1993; Chen et al., 1995; Chai et al., 1996) . In addition, several reports have suggested that LPC activates protein tyrosine kinase in various cells (Watson and Gold, 1997; Bassa et al., 1999; Legradi et al., 2004) . Moreover, we recently reported that the potentiating effect of LPC on contractions of the rat aorta is accompanied by an increase in the tyrosine-phosphorylation of proteins, and that both genistein and tyrphostin B42 attenuate the potentiating effect of LPC on high-K + -induced contraction (Suenaga and Kamata, 2002) . Thus, we suggested that LPC was altered vasomotor response via the activation of tyrosine kinase. When, in the present study, endothelial-denuded aortic strips were pretreated with LPC, the genistein-induced relaxation response was significantly attenuated (Fig. 4, Table 1 ). These results suggested that LPC and genistein were antagonized the tyrosine kinase activity in the aortic smooth muscle. Although the G-VI-and G-II-induced relaxations tended to be attenuated in the presence of LPC (Fig. 4, Table 1 ), G-VI and G-II were more effective at inducing relaxation when LPC was present than genistein was when LPC was absent (Fig. 4, Table 1 ). Furthermore, the SNP-induced relaxation was not attenuated by LPC treatment (Fig. 5, Table 1) . Again, the G-VI-and G-II-induced relaxations remaining in the presence of ODQ were similar to the genistein-induced relaxation (Fig. 3) . Taken together, these results suggest that LPC impairs relaxation in the endothelium-denuded rat aorta via an activation of tyrosine kinase, not via an impairment of NO-signaling, and that our two new compounds have, like genistein, the ability to induce tyrosine kinase inhibition.
It is widely known that genistein, which is a soybean isoflavone, has many beneficial effects on human health (Tham, 1998; Erdman, 2000) . In fact, genistein has been found (a) to be a potent inhibitor of endothelial cell proliferation and angiogenesis (Fotsis et al., 1993) , and (b) to prevent LDL oxidation and protect endothelial cells from the damage inflicted by atherogenic LDL (Kapiotis et al., 1997) . Taking all the above together, we speculate that co-treatment with genistein and NO might be capable of offering a number of tissues protection against a variety of attacks, including oxidative stress.
In conclusion, we found that both of our newly synthesized compounds act as NO-donating tyrosine kinase inhibitors. Following further research, these compounds may prove useful as therapeutic agents in a number of cardiovascular diseases, such as atherosclerosis.
